中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 4
Apr.  2016
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2016  >  32(4): 764-768

Clinical features of Klebsiella pneumoniae liver abscess

DOI: 10.3969/j.issn.1001-5256.2016.04.034

  • Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University

Research funding:

 

  • Published Date: 2016-04-20
    Abstract

  • Objective To analyze the clinical data of Klebsiella pneumoniae liver abscess( KPLA),and to provide a reference for early diagnosis and proper treatment. Methods The etiological features of 156 patients with bacterial liver abscess( BLA) and positive culture results who were hospitalized in The First Hospital Affiliated to Nanjing Medical University from March 2009 to July 2015 were analyzed retrospectively. According to the culture results,BLA patients were divided into KPLA group( 81 patients) and non- KPLA( NKPLA) group( 61 patients),and other positive strains including Escherichia coli were found in the other 14 patients with positive culture results for Klebsiella pneumoniae. The clinical,laboratory,and imaging data of KPLA and NKPLA were compared. The t- test was applied for comparison of normally distributed continuous data between groups,and the Mann- Whitney U test was applied for continuous data with skewed distribution between groups; the chi- square test or Fisher's exact test was applied for comparison of categorical data between groups. Results The most common pathogenic bacteria for BLA were Klebsiella pneumonia. In comparison with the NKPLA group,the KPLA group had a significantly higher proportion of male patients( χ~2= 4. 50,P = 0. 03),a significantly higher proportion of patients with diabetes( χ~2= 27. 28,P < 0. 001),and a significantly lower proportion of patients who complained of abdominal pain( χ~2= 5. 24,P = 0. 02). In the aspects of underlying diseases,the prevalence of biliary tract diseases,previous abdominal surgery,and a history of intraperitoneal tumors showed significant differences between the NKPLA group and the KPLA group( χ~2= 18. 38,20. 87,and 21. 68,all P < 0. 001). As for laboratory examination,the NKPLA group had a significantly greater reduction in hemoglobin compared with the KPLA group( t = 4. 903,P < 0. 001). In terms of imaging examination,most BLA patients showed a single lesion in the right lobe of the liver,but the KPLA group had a significantly higher proportion of patients with the formation of separation( χ~2= 4. 16,P = 0. 04). The patients in both groups experienced complications including pulmonary infection,pleural effusion,and perinephric infection. Most patients were treated with antibiotics combined with puncture,and the KPLA group had a significantly higher response rate than the NKPLA group( 93. 83% vs 80. 33%,χ~2= 6. 02,P = 0. 01).Conclusion The most common pathogenic bacteria for BLA are Gram- negative bacilli,especially Klebsiella pneumoniae. KPLA occurs more commonly in males,and most of the patients have diabetes. The clinical manifestations are not obvious,and the patients tend to develop the complications such as pleural effusion and pulmonary infection. Imaging examination should be performed as early as possible and proper treatment should be given in time.

     

    • FullText(HTML)
    • References(14)
  • [1]ALSAIF HS,VENKATESH SK,CHAN DS,et al.CT appearance of pyogenic liver abscesses caused by Klebsiella pneumoniae[J].Radiology,2011,260(1):129-138.
    [2]CHEN YC,LIN CH,CHANG SN,et al.Epidemiology and clinical outcome of pyogenic liver abscess:an analysis from the National Health Insurance Research Database of Taiwan,2000-2011[J].J Microbiol Immunol Infect,2014.[Epub ahead of print]
    [3]LOK KH,LI KF,LI KK,et al.Pyogenic liver abscess:clinical profile,microbiological characteristics,and management in a Hong Kong hospital[J].J Microbiol Immunol Infect,2008,41(6):483-490.
    [4]GONG J,DAI W,PAN ZG.Pyogenic liver abscess:a clinical analysis of 118 cases[J].Chin J Gen Pract,2013,12(3):211-213.(in Chinese)龚剑,戴维,潘志刚.细菌性肝脓肿118例临床分析[J].中华全科医师杂志,2013,12(3):211-213.
    [5]GUO JJ,WANG HZ,LI J,et al.Pathogenic distribution and drug resistance analysis of 39 cases of bacterial liver abscess[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2015,9(1):69-72.(in Chinese)郭晶晶,王慧珠,李娟,等.39例细菌性肝肿脓患者的病原学分布及耐药性分析[J/CD].中华实验和临床感染病杂志:电子版,2015,9(1):69-72.
    [6]XU YS,ZHENG JY,ZHANG S,et al.The small fiber neuropathy in patients with diabetic peripheral neuropathy[J].Chin J Nerv Ment Dis,2008,34(10):591-593.(in Chinese)徐迎胜,郑菊阳,张朔,等.糖尿病周围神经病的小纤维损害[J].中国神经精神疾病杂志,2008,34(10):591-593.
    [7]STROTMEYER ES,de REKENEIRE N,SCHWARTZ AV,et al.The relationship of reduced peripheral nerve function and diabetes with physical performance in older white and black adults:the Health,Aging,and Body Composition(Health ABC)study[J].Diabetes Care,2008,31(9):1767-1772.
    [8]SIU LK,YEH KM,LIN JC,et al.Klebsiella pneumoniae liver abscess:a new invasive syndrome[J].Lancet Infect Dis,2012,12(11):881-887.
    [9]MOORE R,O'SHEA D,GEOGHEGAN T,et al.Community-acquired Klebsiella pneumoniae liver abscess:an emerging infection in Ireland and Europe[J].Infection,2013,41(3):681-686.
    [10]YU SC,HO SS,LAU WY,et al.Treatment of pyogenic liver abscess:prospective randomized comparison of catheter drainage and needle aspiration[J].Hepatology,2004,39(4):932-938.
    [11]PANG TC,FUNG T,SAMRA J,et al.Pyogenic liver abscess:an audit of 10 years'experience[J].World J Gastroenterol,2011,17(12):1622-1630.
    [12]YANG XP,WANG LP,LUO Y,et al.Clinical value of interventional therapy with ultrasound guided in AIDS patients with liver abscess[J/CD].Chin J Liver Dis:Electronic Edition,2015,7(1):77-79.(in Chinese)杨学平,王丽萍,罗艳,等.超声引导下介入治疗艾滋病合并肝脓肿的临床价值[J/CD].中国肝脏病杂志:电子版,2015,7(1):77-79.
    [13]ALKOFER B,DUFAY C,PARIENTI JJ,et al.Are pyogenic liver abscesses still a surgical concern?A Western experience[J].HPBSurg,2012,2012:316013.
    [14]LO JZ,LEOW JJ,NG PL,et al.Predictors of therapy failure in a series of 741 adult pyogenic liver abscesses[J].J Hepatobiliary Pancreat Sci,2015,22(2):156-165.
    • Relative Articles

  • Relative Articles

    [1]Li Na, Gou Wei, Cui WeiLi. Efficacy of telbivudine combined with adefovir dipivoxil and pegylated interferon combined with entecavir as antiviral therapy for chronic hepatitis B: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(9): 1714-1716. doi: 10.3969/j.issn.1001-5256.2016.09.015
    [2]Yang DongQiang, Chen Fang, Kang Yi, Ding GangQiang, Xiao ErHui, Peng Zhen, Shang Jia. Genotypes and resistance loci in patients with chronic hepatitis B achieving virologic breakthrough in treatment with lamivudine combined with adefovir after developing drug resistance in treatment with lamivudine alone[J]. Journal of Clinical Hepatology, 2016, 32(3): 480-483. doi: 10.3969/j.issn.1001-5256.2016.03.016
    [3]Zhang Wen, Yu JianGuo, Zhu GuiZhong, Zhao ZhanDong, Wang XiaoWei. Clinical efficacy of entecavir combined with adefovir in chronic hepatitis B patients with high viral load[J]. Journal of Clinical Hepatology, 2014, 30(11): 1169-1172. doi: 10.3969/j.issn.1001-5256.2014.11.019
    [4]Huang MeiJin, Tan HouJi, He YanZhuan, Huang QiWen, Zhou YaoNan, Qiu HaiXian. Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(7): 636-638. doi: 10.3969/j.issn.1001-5256.2014.07.015
    [5]Ruan BingWei, Lu XiaoJu, Lin YanMing, Chen RongCe, Chen XinZhi, Ceng GuangZhong, Liu YanPing. Evaluation of adverse reactions induced by adefovir dipivoxil in 85 chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2013, 29(2): 104-106.
    [6]Ma YanHong. Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(8): 631-632. doi: 10.3969/j.issn.1001-5256.2013.08.020
    [7]Yan HaiMing, Chen JianHua, Ye YiNong, Long Hui, Wang XiangHuai. Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B:preliminary comparative study[J]. Journal of Clinical Hepatology, 2013, 29(7): 508-511. doi: 1001-5256 (2013) 07-0508-04
    [8]Song MinNing, Huang WenQi, Min Feng, Hong MeiZhu, Fan RongHua, Wu WeiBing, Zhang Li. The efficacy of 3 years adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance[J]. Journal of Clinical Hepatology, 2012, 28(1): 29-32.
    [9]Liu LongGen, Ye ChunYan, Tong XueCheng. Maintenance of negative HBV DNA in patients with chronic hepatitis B during 96 weeks followup with active replacement of Adefovir dipivoxil with Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(3): 292-294.
    [10]Geng JianZhang, Fan XiaoHong, Lu HaiYing, Li Jing, Tian XiuLan, Xu XiaoYuan. The evaluation of de novo combination of antiviral treatment to hepatitis B patients with decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(8): 837-839+843.
    [11]Gu QiangYe, Li Qin, Ge XiuLin. Observation of long-term efficacy of different treatment protocol of Adefovir dipivoxil in chronic hepatitis B patients with Lamivudine-resistance[J]. Journal of Clinical Hepatology, 2011, 27(4): 411-413.
    [12]Song MinNing, Zhang Li, Huang WenQi, Min Feng. Treatment of chronic hepatitis B with Adefovir dipivoxil:A 3 years observation of clinical efficacy and drug resistance[J]. Journal of Clinical Hepatology, 2010, 26(1): 22-24.
    [13]Yang YaFang, Yang XiaoPing, Dong JianGuo, Wang ZhiGang, Liu YanPing, Zhao TieJun, Gao Feng.

    Analysis of short-term efficacy of entecavir and adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B

    [J]. Journal of Clinical Hepatology, 2010, 26(3): 326-327.
    [14]Zhu FeiYan. The clinical effect Adefovir dipivoxil in Lamivudine resistant HBeAg positive chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2010, 26(5): 517-518.
    [19]Cao TianGao, Li JingNan, Shi YunZhen, Li ChaoXia. The clinical study of foscarnet sodium combined with adefovir dipivoxil for lamivudine-resistant patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(4): 248-250.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(11)

    1. 肖春桃，李贤秋，甘佩灵，潘潇，周贤. 基于倾向性评分匹配分析门静脉血栓对肝硬化患者预后的影响. 临床肝胆病杂志. 2021(08): 1829-1835 . 本站查看
    2. 王彤，牛焕章，杜廷伟，魏乐群. 乙型肝炎肝硬化患者门静脉血栓发生的影响因素及抗凝治疗效果研究. 深圳中西医结合杂志. 2021(17): 134-136 .
    3. 姜炅，袁佳，史海涛，戴社教. 血清ALT、AST联合NFS评分对非酒精性脂肪性肝硬化患者食管胃底静脉曲张严重程度的评估价值. 中西医结合肝病杂志. 2020(04): 314-317 .
    4. 李英，高磊，胡扬喜，胡德升. 低分子肝素钙联合右旋糖酐在肝硬化门静脉高压症术后静脉血栓形成预防中的应用. 肝脏. 2019(07): 788-790 .
    5. 吕靖，董思思，顾宏图，赵长青，刘成海. 肝硬化并发门静脉血栓的危险因素及中医证候特点. 临床肝胆病杂志. 2019(10): 2210-2213 . 本站查看
    6. 陈仙艳. 肝硬化合并上消化道出血患者门静脉血栓形成危险因素分析与护理. 护理实践与研究. 2019(18): 13-15 .
    7. 牟思玉，杨哲，吴力群，邱轩，郭珈铭. 肝硬化门静脉高压脾切除术后门静脉血栓形成的预测因素分析. 临床肝胆病杂志. 2018(01): 106-111 . 本站查看
    8. 张津瑜，陈文显，沈华，王雁，张国雷，慎华平，吴万波，魏云海. 大鼠门静脉系统血栓形成模型的建立和观察. 中国普通外科杂志. 2018(06): 724-731 .
    9. 邢文立，李谦. 重症监护病房肝病患者的血栓预防与出血控制. 临床肝胆病杂志. 2018(10): 2237-2240 . 本站查看
    10. 李志州，向俊峰，周威，唐亮. 探讨门脉高压及外伤性脾破裂行脾切除术后血小板升高及门静脉血栓形成情况. 肝胆外科杂志. 2018(04): 280-282 .
    11. 王士浩，张宏伟. 肝硬化合并门静脉血栓形成危险因素的病例对照研究. 中国中西医结合消化杂志. 2017(11): 867-870 .

    Other cited types(12)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 15.1 %FULLTEXT: 15.1 %META: 80.5 %META: 80.5 %PDF: 4.4 %PDF: 4.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.7 %其他: 4.7 %其他: 0.6 %其他: 0.6 %Bengaluru: 0.2 %Bengaluru: 0.2 %China: 0.7 %China: 0.7 %India: 0.2 %India: 0.2 %Japan: 0.1 %Japan: 0.1 %Kennedy Town: 0.2 %Kennedy Town: 0.2 %North Point: 0.2 %North Point: 0.2 %Seattle: 0.1 %Seattle: 0.1 %United States: 0.2 %United States: 0.2 %[]: 0.4 %[]: 0.4 %上海: 9.5 %上海: 9.5 %东莞: 0.6 %东莞: 0.6 %中卫: 0.1 %中卫: 0.1 %佛山: 0.2 %佛山: 0.2 %佳木斯: 0.1 %佳木斯: 0.1 %北京: 9.3 %北京: 9.3 %南京: 0.6 %南京: 0.6 %南宁: 0.1 %南宁: 0.1 %南阳: 0.1 %南阳: 0.1 %印度泰米尔纳德: 0.1 %印度泰米尔纳德: 0.1 %厦门: 0.1 %厦门: 0.1 %台北: 0.1 %台北: 0.1 %台州: 0.1 %台州: 0.1 %合肥: 0.3 %合肥: 0.3 %周口: 0.1 %周口: 0.1 %哈尔滨: 0.1 %哈尔滨: 0.1 %唐山: 0.1 %唐山: 0.1 %喀什: 0.2 %喀什: 0.2 %圣地亚哥: 0.1 %圣地亚哥: 0.1 %大连: 0.4 %大连: 0.4 %天津: 0.4 %天津: 0.4 %常德: 0.1 %常德: 0.1 %广州: 1.0 %广州: 1.0 %张家口: 1.4 %张家口: 1.4 %成都: 0.2 %成都: 0.2 %扬州: 0.3 %扬州: 0.3 %无锡: 0.2 %无锡: 0.2 %晋城: 0.2 %晋城: 0.2 %杭州: 0.5 %杭州: 0.5 %柳州: 0.1 %柳州: 0.1 %武汉: 0.3 %武汉: 0.3 %水牛城: 0.1 %水牛城: 0.1 %永州: 0.2 %永州: 0.2 %沈阳: 0.2 %沈阳: 0.2 %沈阳市和平区: 0.1 %沈阳市和平区: 0.1 %泰安: 0.2 %泰安: 0.2 %泰州: 0.3 %泰州: 0.3 %洛阳: 0.4 %洛阳: 0.4 %济南: 0.6 %济南: 0.6 %海得拉巴: 0.1 %海得拉巴: 0.1 %深圳: 0.5 %深圳: 0.5 %渭南: 0.1 %渭南: 0.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %百色: 0.2 %百色: 0.2 %眉山: 0.1 %眉山: 0.1 %石嘴山: 0.1 %石嘴山: 0.1 %石家庄: 0.1 %石家庄: 0.1 %秦皇岛: 0.2 %秦皇岛: 0.2 %米兰: 0.1 %米兰: 0.1 %美国伊利诺斯芝加哥: 0.1 %美国伊利诺斯芝加哥: 0.1 %聊城市东昌府区: 0.1 %聊城市东昌府区: 0.1 %芒廷维尤: 38.2 %芒廷维尤: 38.2 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.1 %苏州: 0.1 %莫斯科: 0.6 %莫斯科: 0.6 %莱芜: 0.1 %莱芜: 0.1 %菏泽: 0.2 %菏泽: 0.2 %萍乡: 0.1 %萍乡: 0.1 %葵涌: 0.1 %葵涌: 0.1 %衢州: 0.1 %衢州: 0.1 %西宁: 14.2 %西宁: 14.2 %西安: 2.2 %西安: 2.2 %西安市新城区: 0.1 %西安市新城区: 0.1 %许昌: 0.1 %许昌: 0.1 %诺沃克: 0.1 %诺沃克: 0.1 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.0 %运城: 1.0 %郑州: 0.2 %郑州: 0.2 %重庆: 0.1 %重庆: 0.1 %长春: 0.6 %长春: 0.6 %长沙: 2.2 %长沙: 2.2 %长治: 0.1 %长治: 0.1 %雅安: 1.0 %雅安: 1.0 %青岛: 0.4 %青岛: 0.4 %香港: 0.2 %香港: 0.2 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.2 %黄冈: 0.2 %其他其他BengaluruChinaIndiaJapanKennedy TownNorth PointSeattleUnited States[]上海东莞中卫佛山佳木斯北京南京南宁南阳印度泰米尔纳德厦门台北台州合肥周口哈尔滨唐山喀什圣地亚哥大连天津常德广州张家口成都扬州无锡晋城杭州柳州武汉水牛城永州沈阳沈阳市和平区泰安泰州洛阳济南海得拉巴深圳渭南湘潭漯河百色眉山石嘴山石家庄秦皇岛米兰美国伊利诺斯芝加哥聊城市东昌府区芒廷维尤芝加哥苏州莫斯科莱芜菏泽萍乡葵涌衢州西宁西安西安市新城区许昌诺沃克贵阳赤峰运城郑州重庆长春长沙长治雅安青岛香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2818) PDF downloads(453) Cited by(23)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2462]YesterdayPV[4905]TodayIP[103]TodayPV[185]Online[46]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return